Sep 30, 2022 11:00 JST
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
TOKYO and CENTER VALLEY, PA., Sep 30, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT(TM) Open Fine Jaw Type X surgical energy devices for open surgery. With a new thermal shield, the THUNDERBEAT Open Fine Jaw Type X surgical energy device is designed to support safer procedures.[i] The device is available commercially in Japan. The commercial launch of the product in Europe, the U.S., and South Korea is expected in October 2022, with continued launches in other countries and regions following.
This device is part of Olympus' THUNDERBEAT portfolio of hybrid energy devices that deliver both ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery. The THUNDERBEAT hybrid devices eliminate the need for multiple instruments during the surgery, contributing to efficiency in the operating room and reduced operation time.[ii]
"This latest addition to our differentiated THUNDERBEAT line of products continues to deliver on Olympus' commitment to offering hospitals a full portfolio of Advanced Energy devices providing best-in-class functionality for numerous procedures and specialties in minimally invasive and open surgery," said Phil Roy, Global Vice President and General Manager of the Surgical Devices Business Unit.
The THUNDERBEAT(TM) Open Fine Jaw Type X device is designed for open surgical procedures that require delicate and fine tissue dissection, such as in thyroidectomy or radical neck dissection. The new thermal shield improves the thermal profile on the grasping surface, which reduces the risk of unintended heat damage to nearby tissue, nerves and other structures.[i] The jaw design maintains a finely curved tip for precise dissection and enhanced visibility during use.[i]
- New Thermal Shield Supports Safer Procedures
The newly developed thermal shield at the distal tip slows heat transfer from the probe to the exterior surface of the jaw and reduces the risk of unintended heat damage to surrounding tissue and vessels.[i]
- Fine Shape of Distal Tip Supports Precise Procedures
The slim shape of the distal tip supports precise tissue management capabilities including fine dissection and firm grasping force, cutting and sealing to the tip of the device, and blunt dissection.[i]
- Simultaneous Output of Two Energies Enables a Variety of Operations with One Device
Delivering simultaneous bipolar and ultrasonic energy enables fast, hemostatic cutting, easy dissection, and reliable vessel sealing and division. A separate advanced bipolar[i] function enables vessel sealing and spot coagulation without cutting, when desired.
The THUNDERBEAT(TM) Open Fine Jaw Type X device is a single use hybrid ultrasonic and bipolar electrosurgical instrument intended for use in open surgery. This device should not be used for tubal sterilization or tubal coagulation for sterilization procedures. Use with caution in patients with electronic implants, such as a cardiac pacemaker, or nerve simulators, to avoid possible hazard to patients due to interference. Before use, thoroughly review the product manual and use the equipment as instructed.
The THUNDERBEAT Open Fine Jaw Type X device is manufactured by Olympus Medical Systems Corporation.
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people's lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include a wide range of medical devices to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
[i] Data on file with Olympus as of May 11, 2020
[ii] Data on file with Olympus as of June 26, 2015
Natsuki Inoue - email@example.com
Jessica Lee - firstname.lastname@example.org
Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYs] https://www.olympus-global.com
Sectors: BioTech, Healthcare & Pharm, MedTech
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
Blockpass releases crypto's first Unhosted Wallet KYC
Dec 02, 2022 14:00 JST
TOYOTA GAZOO Racing Launches GR Corolla Sales Efforts with Lotteries in Japan
Dec 02, 2022 13:48 JST
DENSO Receives IEEE Corporate Innovation Award for Developing and Spreading Use of QR Code
Dec 02, 2022 11:29 JST
NEC and SINAI Technologies Collaborate to Create Pathways to Decarbonization
Dec 02, 2022 09:26 JST
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
Dec 01, 2022 20:09 JST
Honda Unveils Next-generation Technologies of Honda SENSING 360 and Honda SENSING Elite
Dec 01, 2022 19:01 JST
MHI Publishes Integrated Report "MHI Report 2022"
Nov 30, 2022 18:07 JST
Mitsubishi Heavy Industries Engineering to be Integrated into MHI
Nov 30, 2022 16:02 JST
NEC Orchestrating Future Fund, an Ecosystem-type CVC Fund, Completes Final Close for US$140 Million
Nov 30, 2022 15:15 JST
Mitsubishi Power to Upgrade Two Gas Turbines at Tuas Power to Achieve 16.9 kilo-tonnes of Carbon Emissions Reduction Annually
Nov 30, 2022 14:55 JST
ExxonMobil, Mitsubishi Heavy Industries Form Carbon Capture Technology Alliance
Nov 30, 2022 11:56 JST
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Nov 30, 2022 10:21 JST
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
Nov 30, 2022 09:31 JST
D3eSports Announces REV3AL Partnership for Virtual-to-Real E-Racing Programs
Nov 30, 2022 02:20 JST
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
Nov 29, 2022 19:28 JST
Tokyo Gas, Osaka Gas, Toho Gas and Mitsubishi Collaborate to Produce e-methane in the US and Transport It to Japan, Utilizing Cameron LNG in Louisiana
Nov 29, 2022 19:12 JST
PLN Nusantara Power and Mitsubishi Power's Muara Karang Power Plant Recognized as "Project of the Year" at Asian Power Awards 2022
Nov 29, 2022 19:00 JST
Pie Systems Japan Signs a Strategic Partnership Agreement with JAPAN POST BANK
Nov 29, 2022 15:00 JST
Hexagon, Fujitsu support Stuttgart's urban digital twin project
Nov 29, 2022 12:35 JST
JCB identifies India as a key growth market for European merchants and acquirers to further propel digital payments and online spending
Nov 29, 2022 12:00 JST